+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Psoriasis - Pipeline Review, H2 2019

  • ID: 4866576
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 803 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • Immunic Inc
  • Midatech Pharma Plc
  • Promethera Biosciences SA
  • MORE
Psoriasis - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis - Pipeline Review, H2 2019, provides an overview of the Psoriasis (Immunology) pipeline landscape.

Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Psoriasis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 1, 25, 38, 62, 3, 126, 41 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 4 molecules, respectively.

Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • Immunic Inc
  • Midatech Pharma Plc
  • Promethera Biosciences SA
  • MORE
Introduction
Psoriasis - Overview
Psoriasis - Therapeutics Development
Psoriasis - Therapeutics Assessment
Psoriasis - Companies Involved in Therapeutics Development
Psoriasis - Drug Profiles
Psoriasis - Dormant Projects
Psoriasis - Discontinued Products
Psoriasis - Product Development Milestones
Appendix

List of Tables
Table 1: Number of Products under Development for Psoriasis, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 8: Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 9: Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Table 10: Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Table 11: Number of Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Table 12: Number of Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Table 13: Number of Products under Development by Universities/Institutes, H2 2019
Table 14: Products under Development by Companies, H2 2019
Table 15: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 16: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 17: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 18: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 19: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 20: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 21: Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Table 22: Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Table 23: Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Table 24: Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Table 25: Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Table 26: Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Table 27: Products under Development by Companies, H2 2019 (Contd..13), H2 2019
Table 28: Products under Development by Companies, H2 2019 (Contd..14), H2 2019
Table 29: Products under Development by Companies, H2 2019 (Contd..15), H2 2019
Table 30: Products under Development by Companies, H2 2019 (Contd..16), H2 2019
Table 31: Products under Development by Companies, H2 2019 (Contd..17), H2 2019
Table 32: Products under Development by Universities/Institutes, H2 2019
Table 33: Number of Products by Stage and Target, H2 2019
Table 34: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 35: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Table 36: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Table 37: Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Table 38: Number of Products by Stage and Mechanism of Action, H2 2019
Table 39: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 40: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Table 41: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Table 42: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Table 43: Number of Products by Stage and Route of Administration, H2 2019
Table 44: Number of Products by Stage and Molecule Type, H2 2019
Table 45: Psoriasis - Pipeline by 3SBio Inc, H2 2019
Table 46: Psoriasis - Pipeline by AbbVie Inc, H2 2019
Table 47: Psoriasis - Pipeline by Abcentra LLC, H2 2019
Table 48: Psoriasis - Pipeline by AbClon Inc, H2 2019
Table 49: Psoriasis - Pipeline by Abeome Corp, H2 2019
Table 50: Psoriasis - Pipeline by AbGenomics International Inc, H2 2019
Table 51: Psoriasis - Pipeline by Abivax SA, H2 2019
Table 52: Psoriasis - Pipeline by Accuitis Pharmaceuticals Inc, H2 2019
Table 53: Psoriasis - Pipeline by Aclaris Therapeutics Inc, H2 2019
Table 54: Psoriasis - Pipeline by Actinobac Biomed Inc, H2 2019
Table 55: Psoriasis - Pipeline by ActoBio Therapeutics Inc, H2 2019
Table 56: Psoriasis - Pipeline by Aerie Pharmaceuticals Inc, H2 2019
Table 57: Psoriasis - Pipeline by Affibody AB, H2 2019
Table 58: Psoriasis - Pipeline by Affilogic SAS, H2 2019
Table 59: Psoriasis - Pipeline by Agragen LLC, H2 2019
Table 60: Psoriasis - Pipeline by Akeso Biopharma Inc, H2 2019

List of Figures
Figure 1: Number of Products under Development for Psoriasis, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 3SBio Inc
  • AbbVie Inc
  • Abcentra LLC
  • AbClon Inc
  • Abeome Corp
  • AbGenomics International Inc
  • Abivax SA
  • Accuitis Pharmaceuticals Inc
  • Aclaris Therapeutics Inc
  • Actinobac Biomed Inc
  • ActoBio Therapeutics Inc
  • Aerie Pharmaceuticals Inc
  • Affibody AB
  • Affilogic SAS
  • Agragen LLC
  • Akeso Biopharma Inc
  • Alfacyte Ltd
  • Allianz Pharmascience Ltd
  • Almirall SA
  • Aluda Pharmaceuticals Inc
  • Alvotech ehf
  • AmDerma Pharmaceuticals LLC
  • Amgen Inc
  • AnaptysBio Inc
  • AntalGenics SL
  • AnTolRx Inc
  • Apidel SA
  • Apimeds Inc
  • Applied Biology Inc
  • Arbor Pharmaceuticals LLC
  • Arcutis Inc
  • Arrien Pharmaceuticals LLC
  • AstraZeneca Plc
  • Athenex Inc
  • Atlantic Bio Sci LLC
  • Aurigene Discovery Technologies Ltd
  • Bayer AG
  • Beijing Fogangren Bio-Pharm Tech Co Ltd
  • Beijing Guiqianjin Medical Technology Co Ltd
  • Beijing Northland Biotech Co Ltd
  • BioApex sro
  • Biocon Ltd
  • BioLingus AG
  • Biomendics LLC
  • Biomimetix JV LLC
  • BioXpress Therapeutics SA
  • BirchBioMed Inc
  • Boehringer Ingelheim International GmbH
  • Boston Pharmaceuticals Inc
  • Botanix Pharmaceuticals Ltd
  • Brickell Biotech Inc
  • Bristol-Myers Squibb Co
  • c-a-i-r Biosciences GmbH
  • C4X Discovery Holdings Plc
  • CalciMedica Inc
  • Can-Fite BioPharma Ltd
  • Canvax Biotech SL
  • Celgene Corp
  • Celon Pharma SA
  • CheckPoint Immunology Inc
  • ChemoCentryx Inc
  • ChironWells GmbH
  • Coegin Pharma AS
  • Coherus BioSciences Inc
  • Compugen Ltd
  • Concenter BioPharma Silkim Ltd
  • Crescita Therapeutics Inc
  • Curapel Ltd
  • Cythera Inc
  • Daiichi Sankyo Co Ltd
  • Dalriada Therapeutics Inc
  • Dermavant Sciences Inc
  • DM Bio Ltd
  • DNX Biopharmaceuticals Inc
  • Dr. August Wolff GmbH & Co KG Arzneimittel
  • DURECT Corp
  • Eli Lilly and Co
  • ELORAC Inc
  • Emeriti Pharma AB
  • Escalier Biosciences BV
  • Eternity Bioscience Inc
  • Evelo Biosciences Inc
  • Exicure Inc
  • Fujifilm Kyowa Kirin Biologics Co Ltd
  • FunPep Co Ltd
  • FYB202 GmbH & Co KG
  • Galapagos NV
  • Galderma SA
  • Genentech Inc
  • GeneScience Pharmaceuticals Co Ltd
  • Genfit SA
  • Genrix (Shanghai) Biopharmaceutical Co Ltd
  • GlaxoSmithKline Plc
  • GlycoMar Ltd
  • Helix BioMedix Inc
  • Hengenix Biotech Inc
  • HitGen LTD
  • Huabo Biopharm Co Ltd
  • Hualan Biological Engineering Inc
  • Hydra Biosciences Inc
  • Hypo-Stream Ltd
  • IMGENEX India Pvt Ltd
  • Immune Pharmaceuticals Inc
  • Immungenetics AG
  • Immunic Inc
  • Immunwork Inc
  • Innovimmune Biotherapeutics Inc
  • InSight Biopharmaceuticals Ltd
  • Inspyr Therapeutics Inc
  • Instituto Biomar SA
  • Istesso Ltd
  • Japan Tobacco Inc
  • JHL Biotech Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • JiangSu Qyuns Therapeutics Co Ltd
  • Johnson & Johnson
  • JS InnoPharm (Shanghai) Ltd
  • Jubilant Biosys Ltd
  • Kadmon Corp LLC
  • Kaken Pharmaceutical Co Ltd
  • Kang Stem Biotech Co Ltd
  • Kangpu Biopharmaceuticals Ltd
  • Kine Sciences
  • Krystal Biotech Inc
  • Kv1.3 Therapeutics
  • Kymab Ltd
  • Lead Pharma Holding BV
  • Leo Pharma AS
  • Link Health Group
  • Lipidor AB
  • Lupin Ltd
  • Lycera Corp
  • Machavert Pharmaceuticals LLC
  • Maruho Co Ltd
  • Matrisys Bioscience Inc
  • MC2 Therapeutics AS
  • Merck KGaA
  • Metrion Biosciences Ltd
  • MetrioPharm AG
  • Mical Pharmaceuticals LLC
  • Midatech Pharma Plc
  • Mycenax Biotech Inc
  • Nektar Therapeutics
  • Nepsone ehf
  • Nestle Skin Health SA
  • NeuClone Pty Ltd
  • Nichi-Iko Pharmaceutical Co Ltd
  • Nimbus Therapeutics LLC
  • NKMAX Co Ltd
  • Nordic Group BV
  • NovaLead Pharma Pvt Ltd
  • Novan Inc
  • Novartis AG
  • Numab Innovation AG
  • Octagon Therapeutics Inc
  • One World Cannabis Ltd
  • Orphagen Pharmaceuticals Inc
  • OSE Immunotherapeutics
  • P & S Nano Ltd
  • Palo BioFarma SL
  • Panaxia Pharmaceutical Industries Ltd
  • Par'Immune SAS
  • Pfizer Inc
  • Pharmapraxis
  • Philogen SpA
  • PinCell srl
  • Pivot Pharmaceuticals Inc
  • Polpharma Biologics
  • PRCL Research Inc
  • Principia Biopharma Inc
  • Progenra Inc
  • Promethera Biosciences SA
  • Provectus Biopharmaceuticals Inc
  • Pyramid Biosciences Inc
  • Reata Pharmaceuticals Inc
  • RedHill Biopharma Ltd
  • Rheos Medicines Inc
  • Rigel Pharmaceuticals Inc
  • RNAx Ltd
  • Samumed LLC
  • Sareum Holdings Plc
  • SBI Biotech Co Ltd
  • selectION Inc
  • Servatus Ltd
  • SFA Therapeutics LLC
  • Shandong Danhong Pharmaceutical Co Ltd
  • Shanghai Celgen Bio-Pharmaceutical Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Shulov Innovative Science Ltd
  • Siam Bioscience Co Ltd
  • Sichuan Haisco Pharmaceutical Co Ltd
  • Sienna Biopharmaceuticals Inc
  • Singh Biotechnology LLC
  • Sinocelltech Ltd
  • Soligenix Inc
  • Spherium Biomed SL
  • sterna biologicals Gmbh & Co KG
  • Sun Pharma Advanced Research Company Ltd
  • Sunny BioDiscovery Inc
  • Suzhou Connect Biopharmaceuticals Ltd
  • Syntrix Biosystems Inc
  • Taro Pharmaceuticals USA Inc
  • Temisis Therapeutics
  • Tianjin Ever Union Biotechnology Co Ltd
  • Tianjin Hemay Bio-Tech Co Ltd
  • Tonghua Dongbao Pharmaceutical Co Ltd
  • UCB SA
  • V Clinbio LLC
  • Vidasym Inc
  • Visionary Pharmaceuticals Inc
  • Voronoi
  • vTv Therapeutics Inc
  • Welichem Biotech Inc
  • Wellstat Therapeutics Corp
  • Wuhan Institute of Biological Products Co Ltd
  • XBiotech Inc
  • Yuhan Corp
  • Zai Lab Ltd
  • Zhejiang Hisun Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll